Vector for inhibition-based high-throughput screen strategy
View Patent ↗A method for screening cells with high level expression of a target protein is disclosed. The method includes introducing into a plurality of host cells a DNA construct that encodes both a target protein and an inhibitor to an endogenous selectable marker in the host cells, screening host cells harboring the DNA construct for the expression of the endogenous selectable marker, and isolating cells with reduced expression of the selectable marker. Also disclosed is a DNA construct configured to express both the target protein and the inhibitor inside the host cell.
1. An expression vector for high-throughput screening of cells harboring the expression vector, comprising:
a first nucleotide sequence, wherein the first nucleotide sequence is a transgene encoding a therapeutic molecule;
a second nucleotide sequence encoding an exogenous selection marker for a host cell;
a third nucleotide sequence encoding an inhibitor to an endogenous selection marker in the host cell; and
one or more regulatory elements that control the expression of the first, second and third nucleotide sequences in the host cell,
wherein the first nucleotide sequence is linked to the second nucleotide sequence by an internal ribosome entry site (IRES).
2. The expression vector of claim 1 , further comprising one or more anti-repressor elements.
3. The expression vector of claim 2 , wherein the one or more anti-repressor elements includes a partial mouse anti-repressor element 40.
4. The expression vector of claim 1 , wherein the inhibitor is an interfering RNA.
5. The expression vector of claim 4 , wherein the interfering RNA is a miR-30-based shRNA.
6. The expression vector of claim 1 , wherein the endogenous selection marker is a fluorescent protein.
7. The expression vector of claim 6 , wherein the fluorescent protein is green fluorescent protein.
8. The expression vector of claim 1 , wherein the exogenous selectable marker is dihydrofolate reductase.
9. The expression vector of claim 1 , wherein the one or more regulatory elements include a CMV IE enhancer.
10. The expression vector of claim 1 , wherein the therapeutic molecule is Herceptin.